Advertisement
Canada markets close in 4 hours 36 minutes

  • S&P/TSX

    21,780.15
    -93.57 (-0.43%)
     

  • S&P 500

    5,009.11
    -62.52 (-1.23%)
     

  • DOW

    37,862.55
    -598.37 (-1.56%)
     

  • CAD/USD

    0.7299
    +0.0001 (+0.02%)
     

  • CRUDE OIL

    82.29
    -0.52 (-0.63%)
     

  • Bitcoin CAD

    87,022.09
    -1,879.98 (-2.11%)
     

  • CMC Crypto 200

    1,372.48
    -10.09 (-0.73%)
     

  • GOLD FUTURES

    2,347.30
    +8.90 (+0.38%)
     

  • RUSSELL 2000

    1,967.44
    -27.99 (-1.40%)
     

  • 10-Yr Bond

    4.7060
    +0.0540 (+1.16%)
     

  • NASDAQ

    15,448.97
    -263.78 (-1.68%)
     

  • VOLATILITY

    17.00
    +1.03 (+6.45%)
     

  • FTSE

    8,068.46
    +28.08 (+0.35%)
     

  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     

  • CAD/EUR

    0.6810
    -0.0009 (-0.13%)
     
BREAKING:

HONDA TO SET UP $15B EV PRODUCTION BASE IN CANADA

Automaker to get up to $5B in government assistance for EV battery, assembly plants

Generation Bio to Present at the 43rd Annual Cowen Healthcare Conference

Generation Bio Co.
·1 min read
Generation Bio Co.
Generation Bio Co.

CAMBRIDGE, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Geoff McDonough, M.D., president and chief executive officer, will participate in the Gene Therapy panel discussion at the 43rd Annual Cowen Healthcare Conference on Monday, March 6th at 10:30 a.m. EST in Boston, MA.

A live webcast of the panel will be available on the investor section of the company’s website at investors.generationbio.com. A replay will be available there for 30 days following the event.

About Generation Bio 
Generation Bio is innovating genetic medicines to provide durable, redosable treatments for people living with rare and prevalent diseases. The company’s non-viral genetic medicine platform incorporates a novel DNA construct called closed-ended DNA, or ceDNA; a unique cell-targeted lipid nanoparticle delivery system, or ctLNP; and a highly scalable capsid-free manufacturing process that uses proprietary cell-free rapid enzymatic synthesis, or RES, to produce ceDNA. The platform is designed to enable multi-year durability from a single dose, to deliver large genetic payloads, including multiple genes, to specific cell types, and to allow titration and redosing to adjust or extend expression levels in each patient. RES has the potential to expand Generation Bio’s manufacturing scale to hundreds of millions of doses to support its mission to extend the reach of genetic medicine to more people, living with more diseases, around the world. 
For more information, please visit www.generationbio.com.

Investors and Media Contact
Maren Killackey
Generation Bio
mkillackey@generationbio.com
857-371-4638